Those of you that understand this awful disease will be glad to learn Roche (NASDAQOTH:RHHBY) has a drug on deck that could send all those rookies back to the minor leagues.

No two multiple sclerosis patients are the same, and despite the recent plethora of options, neurologists still face an awful dilemma. They must decide if a patient's disease is serious enough to warrant treatment with a drug that's highly effective, but potentially fatal.

Or, physicians could prescribe a wonderfully safe drug that might not stop their disease from progressing. Needless to say, it's not a decision taken lightly......


http://www.fool.com/investing/genera...-youve-ne.aspx

Ocrevus (also known as Ocrelizumab, is a humanised monoclonal antibody which targets CD20-positive B cells - these cells are thought to be important in the myelin and axonal damage in people with MS).

it looks encouraging to me - I hope that it works.

Sally actually started a thread about this several weeks ago. I hope it proves to be a miracle for many of us.

http://neurotalk.psychcentral.com/thread233265.html

http://www.msunites.com/genentech-to...us-april-20th/


http://www.nationalmssociety.org/Abo...erapy-Designat


https://en.wikipedia.org/wiki/Ocrelizumab


" Ocrelizumab is a slightly modified version of Biogen/Genentech's existing therapy Rituxan/Rituximab. As Rituxan was approaching FDA approval for treatment of multiple sclerosis, it was simultaneously approaching the end of its patent. To avoid the profit loss of a new treatment that could have been available sooner and eventually in a generic form, Rituxan trials were halted and Ocrelizumab trials quickly began. "